6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05670782 (ClinicalTrials.gov)	July 19, 2022	21/12/2022	A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease	A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KM-819 in Healthy Older Adults and Participants With Parkinson's Disease	Parkinson Disease	Drug: KM-819;Drug: Placebo	FAScinate Therapeutics Inc.	Parexel	Recruiting	40 Years	N/A	All	330	Phase 2	United States
2	NCT03022799 (ClinicalTrials.gov)	November 2016	27/12/2016	Phase I, KM-819 in Healthy Subjects for Parkinson's Disease	A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects	Parkinson's Disease	Drug: KM-819;Drug: Placebo	Kainos Medicine Inc.	NULL	Completed	19 Years	45 Years	All	88	Phase 1	Korea, Republic of